The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Immune checkpoint inhibitors in challenging populations
Open accessAbstract
Immune checkpoint inhibitors, including those targeting the programmed cell death 1/programmed cell death ligand 1 and cytotoxic T lymphocyte antigen 4 pathways, are revolutionizing cancer therapeutics. Both activity and toxicities largely stem from unleashing tumor- or host-specific cytotoxic T cells. Many patients seen in routine clinical practice have not qualified for or have been seriously underrepresented in immune checkpoint inhibitor clinical trials. Thus, a major gap in knowledge regarding the safety and efficacy of these agents persists in many populations, even after regulatory approval. To address this challenge, this review aggregates and synthesizes the available preclinical and clinical data surrounding immune checkpoint inhibitor therapy in challenging clinical populations to assist both academic and community oncologists in treatment decision making. Specifically, this review focuses on the safety and activity of immune checkpoint inhibitors in patients with autoimmune disorders, organ transplant patients, patients with chronic viral infections, patients with ongoing immunosuppressant use, patients with organ dysfunction, pregnant patients, patients with brain metastases, patients at extremes of age, and patients with an impaired functional status. Cancer 2017;123:1904-1911. © 2017 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Thus, the safety and effectiveness of ICI therapy in this special population are unknown.34”
From Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy (2020) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Kaur, A., Webster, M. R., Marchbank, K., Behera, R., Ndoye, A., Kugel, C. H., Dang, V. M., Appleton, J., O’Connell, M. P., Cheng, P., et al. (2016) · Nature · doi:10.1038/nature17392 · Cited by 398
Self-citationRetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A. S., Scott, E. C., Gutierrez, M. E., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,621
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Weber, J. S., D’Angelo, S. P., Minor, D. R., Hodi, F. S., Gutzmer, R., Neyns, B., Höeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,725
Flagged first, then by citations
Research works printed but not linked: 1
- Bethof A, 2015, Age on outcome and toxicity with anti–PD‐1/PD‐L1 therapy in patients with melanoma [abstract], Pigment Cell Melanoma Res, 28, 756
Cited by
Sorted by citations
Items 201–300 of 339
Bhave, P., Pham, A., Gordon, A., & Moore, M. A. (2020) · Immunotherapy · doi:10.2217/imt-2019-0184 · Cited by 7
Dosage of anti-PD-1 monoclonal antibodies: a cardinal open question
Sureda, M., Calvo, E., Mata, J. J., Escudero-Ortíz, V., Martinez-Navarro, E., Catalán-Latorre, A., & Rebollo, J. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02563-3 · Cited by 7
Struckmeier, A., Gosau, M., & Smeets, R. (2024) · Transplantation Reviews · doi:10.1016/j.trre.2024.100882 · Cited by 7
Kawczak, P., Feszak, I. J., & Bączek, T. (2025) · Cancers · doi:10.3390/cancers17172805 · Cited by 6
High-Risk Non-Melanoma Skin Cancers
Lee, T., Oka, T., & Demehri, S. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.05.004 · Cited by 6
Guadagni, S., Chiominto, A., Mackay, A. R., Farina, A. R., Cappabianca, L. A., Puccica, I., Valiyeva, S., & Clementi, M. (2019) · International Journal of Surgery Case Reports · doi:10.1016/j.ijscr.2019.06.064 · Cited by 6
Hughes, M. S., Pietropaolo, M., Vasudevan, M. M., Marcelli, M., & Nguyen, H. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa150 · Cited by 7
Relationship between PD-L1 Expression and Tumor-Infiltrating Lymphocytes in Canine Mammary Tumor
Lopes-Neto, B. E., Nunes‐Pinheiro, D. C. S., Carvalheira, J. G. V., Schmitt, F. C., & Gärtner, M. D. F. (2021) · ACTA SCIENTIAE VETERINARIAE · doi:10.22456/1679-9216.102600 · Cited by 6
Shaw, L., Wiele, A. J., Sircar, K., Wood, C. G., & Msaouel, P. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100349 · Cited by 6
Abunasser, A. A. A., Xue, J., Balawi, E., & Zhu, Y. (2021) · Journal of Oncology · doi:10.1155/2021/6662344 · Cited by 6
Identification of ISCA1 as novel immunological and prognostic biomarker for bladder cancer
Zhou, R., Peng, N., & Wei, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.975503 · Cited by 6
Li, H., Huang, C., Lui, K., Chao, Y., Yeh, C., Lee, L., Huang, Y., Lin, T., Kuo, Y., Huang, M., et al. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101785 · Cited by 6
Immune Checkpoint Inhibitors in Special Populations
Shan, Q., & Lu, H. (2021) · Technology in Cancer Research & Treatment · doi:10.1177/15330338211036526 · Cited by 7
Hanania, H. L., & Lewis, D. J. (2022) · Journal of Dermatological Treatment · doi:10.1080/09546634.2022.2118516 · Cited by 6
Clinical Course of Preexisting Uveitis during Treatment of Lung Cancer with Durvalumab
Ahmad, T. R., Doan, T. A., Gonzales, J. A., Acharya, N. R., & Tsui, E. Y. K. (2019) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2019.1678652 · Cited by 6
Antonuzzo, A., Calabrò, F., Quaglino, P., Roila, F., Sebastiani, G. D., Spina, F., Pasqualetti, G., Cortinovis, D. L., Tagliaferri, E., Peri, A., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0035 · Cited by 7
Ji, S., Liu, H., Pachella, L. A., Stephenson, R. D., Groisberg, R., & Weiss, S. A. (2023) · Frontiers in Transplantation · doi:10.3389/frtra.2023.1284740 · Cited by 5
Brain tumors: Cancer stem-like cells interact with tumor microenvironment
Liu, H., Wang, Y., & Feng, S. (2020) · World Journal of Stem Cells · doi:10.4252/wjsc.v12.i12.1439 · Cited by 6
Bossi, P., & Lorini, L. (2021) · Dermatology Practical & Conceptual · doi:10.5826/dpc.11s2a170s · Cited by 5
Białek, J., Yankulov, S., Kawan, F., Fornara, P., & Theil, G. (2022) · Biomedicines · doi:10.3390/biomedicines10123244 · Cited by 5
Xiong, Y., Song, W., Shen, L., Wang, Y., Zhang, J., Hu, M., Liu, Y., Li, J., Musetti, S., Liu, R., et al. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000168 · Cited by 5
Zhang, Z., Su, J., Li, L., & Du, W. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.666462 · Cited by 5
Locati, L. D., Serafini, M. S., Carenzo, A., Canevari, S., Perrone, F., Orlandi, E. M., Delbue, S., Cavalieri, S., Berzeri, G., Pichiecchio, A., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.799453 · Cited by 5
The impact of immunotherapy on reductions in cancer mortality: Evidence from Medicare
Horn, D., Alpert, A. E., Duggan, M., & Jacobson, M. (2026) · Journal of Health Economics · doi:10.1016/j.jhealeco.2026.103115 · Cited by 4
Young, R. B., Panchal, H. V., Ma, W., Chen, S., Steele, A., Iannucci, A., & Li, T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.980181 · Cited by 4
An evaluation of durvalumab across the spectrum of urothelial carcinoma
Oh, E. L., Redfern, A. D., & Hayne, D. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2405104 · Cited by 3
Piper-Valillo, A. J., Sehgal, K., Costa, D. B., & Rangachari, D. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.05.12 · Cited by 4
Wang, J., Zhou, Y., Yang, Y., & Wu, Z. (2023) · PubMed Central · Cited by 4
Titmuss, E., Yu, I. S., Pleasance, E., Williamson, L., Mungall, K., Mungall, A. J. J., Renouf, D. J., Moore, R. A., Jones, S. J. M., Marra, M. A., et al. (2024) · Current Oncology · doi:10.3390/curroncol31040140 · Cited by 4
Zhou, D., Cui, Y., Liang, T., Wu, Z., Yan, H., Li, Y., Yin, W., Lin, Y., & You, Q. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03755-5 · Cited by 4
Karibe, J., Horiguchi, R., Hanajima, Y., Hashizume, A., Takamoto, D., Kawahara, T., Osaka, K., Teranishi, J.-I., Ueda, N., & Uemura, H. (2025) · Case Reports in Oncology · doi:10.1159/000545733 · Cited by 4
Yu, J., Zhang, Y.-F., Wang, C.-G., Yang, W., & Chen, F. (2025) · Dermatologica Sinica · doi:10.4103/ds.ds-d-24-00059 · Cited by 4
Immunosenescence and Cancer Immunotherapy at Old Age: Basics
Fülöp, T., Witkowski, J. M., Hirokawa, K., Larbi, A., & Pawelec, G. (2018) · Springer eBooks · doi:10.1007/978-3-319-44870-1_77-1 · Cited by 4
The Recipient of a Renal Transplant
Chapman, J. R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-53186-3.00004-8 · Cited by 4
Numakura, K., Kobayashi, M., Muto, Y., Sekine, Y., Takahashi, M., Kashima, S., Yamamoto, R., Koizumi, A., Nara, T., Saito, M., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-77135-6 · Cited by 4
Systemtherapie des Harnblasenkarzinoms
Tamalunas, A. J., Schulz, G. B., Rodler, S., Apfelbeck, M., Stief, C. G., & Casuscelli, J. (2021) · Der Urologe · doi:10.1007/s00120-020-01420-5 · Cited by 4
Guadagni, S., Zoras, O., Fiorentini, G., Masedu, F., Lasithiotakis, K. G., Sarti, D., Farina, A. R., Mackay, A. R., & Clementi, M. (2021) · Journal of Surgical Research · doi:10.1016/j.jss.2021.05.054 · Cited by 4
Zhang, T., Yu, S., & Zhao, S. (2022) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-21-808 · Cited by 4
Warner, B. M., & Baer, A. N. (2021) · Springer eBooks · doi:10.1007/978-3-030-56824-5_7 · Cited by 4
Immunosenescence and Cancer Immunotherapy at Old Age: Basics
Fülöp, T., Witkowski, J. M., Hirokawa, K., Larbi, A., & Pawelec, G. (2020) · Springer eBooks · doi:10.1007/978-3-319-57415-8_77 · Cited by 4
An, J., Han, S., Kim, H. I., & Shim, J. H. (2022) · Hepatology Communications · doi:10.1002/hep4.2025 · Cited by 3
Inhibitory effect and mechanism of hirsuteine on NCI‑H1299 lung cancer cell lines
Xue-lin, Y., Qin, H., Du, B., Peng, Y., Liu, Y., Yao Zong, Y. U. A. N., Meng, J., & Bi-xian, Y. (2023) · Oncology Letters · doi:10.3892/ol.2023.13788 · Cited by 4
Immune-mediated Colitis from Dual Checkpoint Inhibitors
Thalambedu, N., Khan, Y., Zhang, Q., Khanal, S., & Ashfaq, A. A. (2019) · Cureus · doi:10.7759/cureus.6233 · Cited by 4
Sun, H., Huang, Z., Wen, T., Liu, L., Zhu, X., Zhang, E., Li, C., Zhang, X., Wang, J., Fan, J., et al. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s516478 · Cited by 4
Sun, F., Wang, D., Liu, A., Wang, T., Zhang, D., Yao, H., Sun, K., Zhou, Z., Lu, G., & Wu, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.837499 · Cited by 3
Watts, T. E., Jennings, S., Anstey, S., & Roche, D. (2024) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2024.151745 · Cited by 3
Hsu, J. C., Nguyen, P.-A., Chen, Y.-T., Yang, S., Lin, C., Yang, Y., Lin, Y.-C., Hsia, T., Hsieh, H.-C., Wu, J.-S., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.671127 · Cited by 3
Marzuki, N. F. N., & Zakaria, Y. (2022) · Current Cancer Therapy Reviews · doi:10.2174/1573394718666220829125338 · Cited by 3
Pembrolizumab in an HIV-infected patient with glioblastoma
Yuen, C., Bao, S., Pekmezci, M., Mo, F., & Kong, X. (2024) · Immunotherapy · doi:10.1080/1750743x.2024.2362566 · Cited by 3
Atezolizumab in understudied populations with bladder cancer
Stewart, T. F., & Petrylak, D. P. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0200-8 · Cited by 3
Poon, D. M. C., Chan, C. K., Chan, K., Chu, W.-H., Kwong, P. W., Lam, W., Law, K., Lee, E. K., Liu, P., Sze, H. C., et al. (2021) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13581 · Cited by 3
Ferreira, M., Sécher, T., Heuzé‐Vourc'h, N., & Reckamp, K. L. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060912 · Cited by 4
Cammarota, A., Zanuso, V., D’Alessio, A., Pressiani, T., Bozzarelli, S., Personeni, N., & Rimassa, L. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2042253 · Cited by 4
Unusual case of immune-related colitis
Issa, M., & Milioglou, I. (2017) · BMJ Case Reports · doi:10.1136/bcr-2017-221319 · Cited by 3
Asymptomatic Brainstem Lesions and Pachymeningeal Enhancement After anti-PD-1 Therapy
Yuen, C., Rezania, K., Park, D. M., & Reder, A. T. (2020) · Immunotherapy · doi:10.2217/imt-2020-0186 · Cited by 3
Read, R. L., & Thompson, J. F. (2021) · Melanoma Research · doi:10.1097/cmr.0000000000000740 · Cited by 3
Holmes, A. N., Swede, H., Feer, W. M., Pike, D. C., Wang, X., & Hegde, U. P. (2021) · BMC Cancer · doi:10.1186/s12885-021-09001-1 · Cited by 3
Survival Correlates With Adjuvant Choice in Sentinel Node Positive Head and Neck Cutaneous Melanoma
Dadafarin, S., Alvi, M. A., Massa, S. T., Veatch, J. R., & Rizvi, Z. H. (2025) · The Laryngoscope · doi:10.1002/lary.32269 · Cited by 2
Topçu, A. U., Esen, B. H., Bektaş, Ş. N., Selçukbırıcık, F., & Kanbay, M. (2025) · Amyloid · doi:10.1080/13506129.2025.2589197 · Cited by 2
Schneider, C., Pozsgai, M., Németh, C., Battyáni, Z., & Lengyel, Z. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14238591 · Cited by 2
Targeted treatment of metastatic melanoma in a drug‐addicted patient with pre‐existing hepatitis C
Arenbergerová, M., Fialová, A., Arenberger, P., Gkalpakiotis, S., Pásek, M., & Putzová, M. (2018) · Dermatologic Therapy · doi:10.1111/dth.12790 · Cited by 2
Evaluation of Efficacy and Safety of Nivolumab and Pembrolizumab in Elderly Cancer Patients
Kim, H. S., Jeong, H., & Shim, M. K. (2020) · Korean Journal of Clinical Pharmacy · doi:10.24304/kjcp.2020.30.1.11 · Cited by 2
AL161431.1 is identified as a biomarker for bladder cancer progression and immunotherapy response
Zhang, S., Wang, Y., Han, Z., Lu, B., Sun, K., Teng, Z., Jin, C., Li, F., Yuan, H., Guo, F., et al. (2025) · Scientific Reports · doi:10.1038/s41598-024-82425-4 · Cited by 2
NFATC2 target gene signature correlates with immune checkpoint blockade resistance in melanoma
Lawal, B. (2025) · American Journal of Cancer Research · doi:10.62347/eyml2689 · Cited by 2
Beyond Checkpoint Inhibition: Keeping Therapeutic Options Open
Joshi, U. M., Hundal, J., Mata, J. R., Schollenberger, M. D., Warrier, G., Luke, J. J., Lipson, E. J., & Funchain, P. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473856 · Cited by 2
Cemiplimab in the treatment of metastatic basal cell carcinoma
Bapna, M., & Ruiz, E. S. (2025) · Future Oncology · doi:10.1080/14796694.2025.2511568 · Cited by 2
Immunotherapy for Breast Cancer
Costa, K. M. N., de Melo, D. F., Soares, I. L. D. S., Damasceno, B. P. G. D. L., & Oshiro, J. A. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_224-1 · Cited by 2
Case Report: A case of immune checkpoint inhibitor therapy in a patient with multiple sclerosis
Vaddepally, R. K., Sodavarapu, S., Kutadi, A. P., Taylor, W., & Kumar, N. (2020) · F1000Research · doi:10.12688/f1000research.25490.1 · Cited by 2
Cardiovascular Toxicity Associated With Immune Checkpoint Inhibitor Therapy: A Comprehensive Review
Chitsazan, M., Amin, A., Ladel, L., Baig, A., & Chitsazan, M. (2023) · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · doi:10.1097/hpc.0000000000000327 · Cited by 2
Toxicities in Immune Checkpoint Inhibitors
Lee, S. S., Loecher, M., & Puzanov, I. J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54948-6.00011-1 · Cited by 2
Iatrogenic Disease of the Genitourinary Tract
Cathro, H. P. (2019) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000226 · Cited by 1
First report of a very rare complication in a case of nonsmall cell lung carcinoma
Moreira, I., Vilariça, A. S., & Alves, P. M. (2021) · Breathe · doi:10.1183/20734735.0107-2021 · Cited by 1
Inflammatory Bowel Disease and Colorectal Cancer
Glyn, T., & Lightner, A. L. (2023) · Digestive Disease Interventions · doi:10.1055/s-0042-1760425 · Cited by 1
Guan, Z., Wang, H., & Tian, M. (2024) · Biochemical Genetics · doi:10.1007/s10528-024-10767-9 · Cited by 1
Gohil, S., Chen, H., Lewis, W. E., Trivedi, M. V., Aparasu, R. R., & Johnson, M. L. (2024) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2024.102071 · Cited by 1
Early-Stage Renal Cell Carcinoma: Who Needs Adjuvant Therapy?
Paroșanu, A. I., Nititpir, C., Stanciu, I.-M., & Baston, C. (2025) · Biomedicines · doi:10.3390/biomedicines13030543 · Cited by 1
Wang, K., Yang, X., Guo, F., Sun, H., Fang, Y., Jiang, N., & Chen, X. (2025) · BMC Medical Genomics · doi:10.1186/s12920-025-02097-5 · Cited by 1
Current oncological management options for hepato-pancreato-biliary cancers
Alexander, S., & Menon, S. (2025) · Gastrointestinal Nursing · doi:10.12968/gasn.2024.0116r1 · Cited by 1
Breaking Barriers: Immune Checkpoint Inhibitors in Breast Cancer
Dmuchowski, B., Hryniewicz, W. W., BARCZAK, I., Fręśko, K., Szarzyńska, Z., WĘCLEWSKI, H., Ślężak, J. K., Dobosz, P., & Gryczka, H. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics18010034 · Cited by 2
Gohil, S., Chen, H., Lewis, W. E., Trivedi, M. V., Aparasu, R. R., & Johnson, M. L. (2026) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2026.102971 · Cited by 1
Case Report: Immunotherapy-induced Felty syndrome in a patient with metastatic melanoma
Park, L. S., Byrne, C. A., Burridge, H., Zhu, W., Leech, M. T., & Andrews, M. C. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1808710 · Cited by 1
Sciascia, S., Hudson, M., Fritzler, M. J., Satoh, M., & Mähler, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820239-5.00011-5 · Cited by 1
Pregnancy and malignant diseases — principles of management
Kornovski, Y. D., Ivanova, Y., Kostov, S. G., Slavchev, S. H., & Yordanov, A. D. (2021) · Oncology in Clinical Practice · doi:10.5603/ocp.2021.0024 · Cited by 1
Immune Checkpoint Inhibitor Use in Microscopic Colitis
Farha, N., Sleiman, J., Funchain, P., & Philpott, J. R. (2022) · Annals of Internal Medicine Clinical Cases · doi:10.7326/aimcc.2022.0207 · Cited by 1
Ding, Y., Gong, Y., Zeng, H., Song, G., Yu, Z., Fu, B., Liu, Y., Huang, D., & Zhong, Y. (2023) · Aging · doi:10.18632/aging.204827 · Cited by 1
Crocetti, E., Ravaioli, A., Falcini, F., Vattiato, R., Mancini, S., Baldacchini, F., Zamagni, F., Vitali, B., Balducci, C., Bucchi, L., et al. (2024) · Tumori Journal · doi:10.1177/03008916241229649 · Cited by 1
Lessard-Roy, A., Marchand, R., Lemieux, P., Masse, M., Lacerte, A., Carmichael, P., & Laurin, D. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01301-7 · Cited by 1
T cell immunotherapy in hepatitis B Virus related hepatocellular carcinoma
Hafezi, M., Bertoletti, A., & Tan, A. T. (2018) · Hepatoma Research · doi:10.20517/2394-5079.2018.55 · Cited by 1
Infectious Considerations for Patients on Immune Checkpoint Inhibitors
Modi, A., & Mossad, S. B. (2019) · OBM Transplantation · doi:10.21926/obm.transplant.1903085 · Cited by 1
Czarnecka, A. M., & Rutkowski, P. L. (2020) · Oncology in Clinical Practice · doi:10.5603/ocp.2020.0004 · Cited by 1
(2023) · Journal of Population Therapeutics and Clinical Pharmacology · doi:10.47750/jptcp.2023.30.13.025 · Cited by 1
Durkin, M. J., Seoudi, N., & NAIR, R. G. (2021) · Wiley eBooks · doi:10.1002/9781119597797.ch21 · Cited by 1
Rizack, T., & Castillo, J. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00061-x
When to Consider Alternatives to Front-Line Immune Therapies in Metastatic Melanoma
Wang, D. Y., & Johnson, D. B. (2017) · Melanoma Management · doi:10.2217/mmt-2017-0005
Jheengut, Y., Liu, Y. Q., & Liu, L. X. (2019) · journal of nutritional oncology · doi:10.34175/jno201904002
Clinical research progress of immune checkpoint inhibitors in treatment of primary liver cancer
Zhang, J., Ma, Y., Gu, J., & Huo, J.-G. (2020) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v28.i14.605
Shore, N. D. (2020) · Bladder Cancer · doi:10.3233/blc-200362
Novel biomarkers for melanoma immunotherapy
Wong, N. M. A. (2020) · Minerva Access (University of Melbourne)
Non-Rheumatic Immune-Related Adverse Events
Balaji, A., Shankar, B., & Naidoo, J. (2021) · Springer eBooks · doi:10.1007/978-3-030-56824-5_10
Acute pancreatitis induced by drugs used in the treatment of solid malignant neoplasms
Atabiekov, I., Golovin, A. V., FESAK, I. V., Kazimov, K. N., & Dzhansyz, I. N. (2021) · P A Herzen Journal of Oncology · doi:10.17116/onkolog20211001146
Metadata
- Authors
- Johnson, D. B., Sullivan, R. J., & Menzies, A. M.
- Affiliations
- Vanderbilt University Medical Center (US)
- Massachusetts General Hospital (US)
- The University of Sydney (AU)
- Corresponding author
- Johnson, Douglas B.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2017-02-27
- Volume
- 123
- Issue
- 11
- Pages
- 1904-1911
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- PMC
- PMC5445005
- OpenAlex
- W2592187743
- Cited by
- 339
- References
- 78
- Citations by year
- 2026: 10 · 2025: 30 · 2024: 21 · 2023: 32 · 2022: 42 · 2021: 58 · 2020: 71 · 2019: 42 · 2018: 23 · 2017: 10
- FWCI
- 4.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (K23 CA204726)
- Cancer Institute NSW
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- immune checkpoint inhibitors, PD-1/PD-L1 pathway, underrepresented groups, autoimmune disease, organ transplant recipients, chronic viral infection, immunosuppressants, organ dysfunction, pregnancy, brain metastases, elderly patients, treatment safety, treatment efficacy
- MeSH terms
- Ipilimumab, Squamous Cell Carcinoma of Head and Neck, Nivolumab, Age Factors, Antibodies, Monoclonal, Antineoplastic Agents, Autoimmune Diseases, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Female, Graft Rejection, Head and Neck Neoplasms, Humans, Immunosuppressive Agents, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Pregnancy, Pregnancy Complications, Neoplastic, HIV Infections, Immunocompromised Host, Hepatitis B, Chronic, Hepatitis C, Chronic, B7-H1 Antigen, CTLA-4 Antigen, Programmed Cell Death 1 Receptor, Transplant Recipients
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
